TechJournal South
Header

Posts Tagged ‘IPOs’

SciQuest switches IPO plans to Nasdaq

Friday, June 25th, 2010

sciQuestCARY, NC – SciQuest Inc., which sells on-demand supply and procurement software, plans to trade on Nasdaq after launching its initial public offering of stock rather than on the NYSE as originally planned. The company disclosed the change in a filing with the U.S. Securities and Exchange Commission.

SciQuest plans to raise $75 million in the IPO.

The venture-backed company’s investors include Trinity Ventures, Intersouth Partners and River Cities Capital. They helped SciQuest go private when it was previously a public company.

SciQuest is one of the Research Triangle’s turnaround success stories. It came back from the brink of near dissolution under the leadership of CEO Stephen Wiehe, who was recently named Ernst & Young’s Entrepreneur of the Year for the Carolinas.

The company is one of a handful of SaaS pioneers in the Research Triangle.

Wiehe has been a speaker at TechJournal South’s Internet Summit.

See: SciQuest files for $75M IPO, capping a turnaround story

Florida’s Aurora Diagnostics prescribed $335M credit facility

Tuesday, June 22nd, 2010

auroraPALM BEACH GARDENS, FL -Aurora Diagnostics, an anatomic pathology and diagnostics lab that has registered for $150 million IPO, has secured a $335 million credit facility from Barclays Bank. The loan is partially designed to retire other debt, and includes a $225 million senior secured term loan facility and a $110 million senior secured revolving credit facility.

Founded in 2006, the company reported $171 million in revenue in 2009, compared with $159 million in 2008. It had a net income of $9 million in 2009.

We’ve noticed that diagnostics companies and labs are riding high in the face of the aging U.S. population increasing the need for diagnostic services and advances in biotechnology creating new tests on a regular basis.

Previously on TechJournal South:

Aurora Diagnostics files for IPO

Motricity IPO sells fewer shares than expected at low end of range

Friday, June 18th, 2010

MotricityDURHAM, NC – Motricity, which sells mobile Internet and data services, sold fewer shares than expected, 5 million at $10 each, according to Reuters. The Bellevue, WA-based company, founded in Durham, NC, originally filed to sell 6.75 million shares at between $14 and $16, but lowered its price to between $10 and $11, which we reported yesterday.

The company said in an SEC filing that billionaire investor Carl Icahn, who already owns 18.5 percent of the company, wanted to buy 1 million of the IPO shares.

Reuters cited an underwriter as the source of its report. The company will trade on Nasdaq under the symbol “MOTR.”

Motricity raised more than $365 million in venture backing from Advanced Equities, Carl Icahn, New Enterprise Associates, Technology Crossover Ventures, Massey-Burch Capital, Noro Moseley Partners, Intel Capital, Qualcomm Ventures, Sienna Ventures, TriState Investment Group, and Wakefield Group.

Motricity motors back IPO terms

Thursday, June 17th, 2010

MotricityDURHAM, NC - Motricity, a Bellvue, WA-based company founded in Durham, NC, has slashed its proposed IPO terms from 6.75 million shares offered at between $14 and $16 a share to 5.87 million shares offered at beteween $10 and $11 a share.

The company reported the change in a filing with the U.S. Securities and Exchange Commission.

Broadsoft, the Gaithersburg, MD company that makes VoIP software for the telecom industry, priced its IPO earlier this week at the low end of its range, $9 a share, and saw its share price drop after that. It was selling at $8.30 midday Thursday.

In 2009, Motricity reported $113 million in revenue with a net loss of $16 million, down from a net loss in 2008 of $78 million on $103 million in revenue.

Motricity raised more than $365 million in venture backing from Advanced Equities, Carl Icahn, New Enterprise Associates, Technology Crossover Ventures, Massey-Burch Capital, Noro Moseley Partners, Intel Capital, Qualcomm Ventures, Sienna Ventures, TriState Investment Group, and Wakefield Group.

River Cities Capital Funds sees string of SaaS successes

Friday, May 14th, 2010

By Allan Maurer

Rik Vandevenne

Rik Vandevenne

RALEIGH, NC – River Cities Capital Funds has had a string of successful exits among its Software-as-a-Service (SaaS) portfolio companies recently and may soon have another—Cary, NC-based SciQuest, which is lined up to launch an initial public offering of stock.

Raleigh-based River Cities Principal Rik Vandevenne tells us that the firm invested in eight SaaS companies, “primarily in the 2002-2007 timeframe before people really understood the power of the SaaS model.”

SPS Commerce, a St. Paul, Minnesota-based SaaS supply-chain software company, launched a successful IPO April 22 and became the only one of a busy day to trade above its $12 IPO price, opening at $14 on the Nasdaq exchange.

SPS Commerce marks the third successful SaaS portfolio exit for River Cities in the recent past.  In 2007 California-based EVault was sold to Seagate for $185 million as the foundation of their managed data protection services offering, i365. In 2009 McAfee acquired Denver-based MX Logic for $170 million to add hosted email filtering to its “Security as a Service” solution.

Vandevenne points out that such success stories are important because the venture industry is shrinking and funds will have to show good returns to keep investing in high growth companies. He adds, “We think there is an appetite in the public markets for high growth tech companies.”

Actively looking for deals

River Cities, which also has an office in Cinncinnati, Ohio, has been investing in Midwest and Southeast startups for 25 years and has had a Raleigh office for ten, Vandevenne says. “We’re actively investing and looking to make investments,” he adds.

Vandevenne joined Ed McCarthy at the Raleigh office in 2004

“We are investing out of our fourth fund, $120 million, that we raised in 2008. We primarily invest in the Midwest and Southeast which we believe are underserved venture territories and look to partner with visionary entrepreneurs to grow market leading companies.”

Vandevenne says that means “You may have to turn over more stones to find the gems, but not all the gold is in California.”

“We invest in healthcare and information technology companies that are beyond the concept stage and have meaningful revenues and customers that validate the model.

Prepared for follow-on investments

“In healthcare we invest in medical devices, healthcare Services and healthcare IT.” He says that in medical device companies, River Cities looks for those useful to “the average doctor, not just the super specialized surgeon with magic hands,” and where there is a clear path to reimbursement and the money it invests will go primarily to sales and marketing.

“On the information technology side we look for SaaS, Cloud, enterprise software and technology enabled business services.”

Vandevenne says the firm typically invests from $3 million to $6 million initially, but “always reserve significant capital for further investment as things often take longer than one expects.”

He says River Cities is looking for visionary entrepreneurs with a proven model that has revenue of about $2 million annually.

Portfolio companies hiring

We hope some lawmakers in DC are reading this. As more evidence that startup firms and the venture industry are the real job creation engines in the United States, Vandevenne says there are 55 portfolio company jobs listed on River Cities Web site and “That’s only a fraction of the jobs they have open.”

That’s in line with our earlier story noting that many portfolio companies of other regional venture firms also have numerous job openings.

In addition to SciQuest–which Vandevenne could not discuss since it is lined up for an IPO–the firm’s Southeast portfolio companies include Prenova, Afterbot, and Prosero, and EndoChoice,  in Atlanta, Privaris, Charlottesville, VA, High Speed Access in Louisville, KY, and Convey Systems in Charlotte.

Aurora Diagnostics seeks $150M IPO

Friday, April 30th, 2010

PALM BEACH GARDENS, FL – Aurora Diagnostics, a diagnostic lab and anatomic pathology company, has filed for a $150 million initial public offering of stock.

We’ve noticed that diagnostics firms are on a roll this year. Several in the Southeast have made major acquisitions or landed funding. As we’ve pointed out in the past, an aging U.S. population has a lot to do with that, although other factors are also at play.

The company was founded in 2006 as a platform for the acquisition and integration of anatomic pathology and other diagnostic laboratory businesses. Aurora Diagnostics provides liquidity, financial upside, administrative resources, and accelerated growth opportunities to laboratory owners while allowing them to maintain their entrepreneurial approach and operational independence.

The company plans to trade on Nasdaq under the symbol “ARDX.”

The company also provides a bundle of services such as sales and marketing, information and medical technology, accounting and tax, risk management, managed care contracting and follow-on acquisitions to help laboratory owners perform their core business more efficiently and effectively.

It reported $171 million in net 2009 revenue, compared with $159 million in 2008 and net income of $9 million in 2009 vs. $10.7 million in 2008.

Atlanta’s Alimera Sciences IPO raises $72M

Thursday, April 22nd, 2010

ATLANTA – Alimera Sciences Inc. developing prescription eye treatments, has raised about $72 million in an initial public offering of stock.

Alimera sold 6.5 million shares at $11 a share, a significant discount from the proposed pricing of $15 to $17 a share.

It will trade on Nasdaq under the symbol “ALIM.”

Alimera has raised nearly $71 million in venture backing since its founding in June 2003. Investors include Scale Venture Partners, Domain Associates, Intersouth Partners, and Polaris Venture Partners, which all have an 18.44 percent stake. Venrock Associates has a 14.93 percent stake.

The company focuses on diseases affecting the lining in the back of the eye, or retina, because these diseases are either not treated pharmacologically or are in need of improved treatments.

It says it is also testing treatments for a type of age-related macular degeneration.

Alimera set for $87M IPO this week

Tuesday, April 20th, 2010

ATLANTA, GA – Alimera Sciences, a company developing prescription eye treatments hopes to raise $87 million in an initial public offering of stock this week.

The company hopes to sell 6 million shares of stock at between $15 and $17 a share. If it prices in the middle of that range, it would have a market cap of slightly more than $87 million. It plans to trade on Nasdaq under the symbol “ALIM.”

Alimera has raised nearly $71 million in venture backing since its founding in June 2003. Investors include Scale Venture Partners, Domain Associates, Intersouth Partners, and Polaris Venture Partners, which all have an 18.44 percent stake. Venrock Associates has a 14.93 percent stake.

Credit Suisse and Citi serve as co-lead underwriters for the company’s IPO.

The company sold two over-the-counter allergy products and an eye lubricant to Bausch & Lomb for $16.7 million.

The company focuses on diseases affecting the lining in the back of the eye, or retina, because these diseases are either not treated pharmacologically or are in need of improved treatments.

It says it is also testing treatments for a type of age-related macular degeneration.

SciQuest files for $75M IPO, capping a turnaround story

Friday, March 26th, 2010

sciquest logoCARY, NC – In a turnaround story likely to inspire business school case studies, SciQuest Inc., a company selling procurement software, has filed with the U.S. Securities and Exchange Commission to raise up to $75 million in an initial public offering of stock. It plans to list on the NYSE under the symbol SQI, but did not disclose the number of shares it plans to sell.

Founded in 1995 by four entrepreneurs, SciQuest raised four rounds of venture capital and went public before in 2000.

However, the company ran into difficulties establishing its online exchange for laboratory supplies and finally brought in CEO Steve Wiehe in 2001, who began engineering a turnaround.

In 2004, private investors (California’s Trinity Ventures, Durham, NC-based Intersouth Partners and River Cities invested the funds to take it out of the public arena) acquired the company for $25.25 million and removed it voluntarily from the NASDAQ exchange.

The company said it plans to use about $35.5 million of its net proceeds to redeem all of its outstanding shares of preferred stock.

Wiehe and his team refocused SciQuest as one of the first to sell its product on a Software as a Service Model (SaaS). In 2006, as a private company, SciQuest posted its first profits. Wiehe participated in TechJournal South’s first Internet Summit (the next is coming up in Raleigh in November: www.internetsummit.com)

For the year ending in December 2009, SciQuest reported net income of $2.63 million from revenues of $36.8 million.

For the history of the company, see these previous stories on TechJournal South:

SciQuest: A turnaround story

Going private: SciQuest’s turnaround, part 2

Switching to software as a service saved SciQuest

Regenerative tissue firm Tengion files for $40M IPO

Wednesday, March 17th, 2010

Dr. Anthony Atala, co-scientific founder, Tengion

Dr. Anthony Atala, co-scientific founder, Tengion

EAST NORRITON, PA – Tengion, a company that creates working organs using a patient’s own cells, plans to raise $40 million in an initial public offering of stock. Tengion has a research laboratory and pilot facility in Winston Salem, NC, where co-scientific founder Dr. Anthony Atala heads the Wake Forest Institute for Regenerative Medicine.

Tengion plans to offer 4.4 million shares at $8 to $10 a share. It will trade on Nasdaq under the symbol TNGN.

The company’s patented integrated technology platform  was developed over the past two decades by scientists at Children’s Hospital Boston (a teaching affiliate of Harvard Medical School), MIT, and the Wake Forest Institute for Regenerative Medicine.

It harnesses the body’s ability to regenerate tissues and organs, and has the potential to allow adults and children with organ failure to have functioning organs created from their own tissues.

Founded in 2003, the company has no revenue.

company owns or licenses over 30 US patents and patent applications and over 100 international patents and filings related to its platform and nine product candidates.

It has a urological treatment in Phase II clinical trials.

We have always been impressed with the progress of regenerative medicine in recent years and Dr. Atala’s work is at the forefront.

Dr. Atala and his lab have created working human bladders on cell scaffolds, a unique sort of construction work. Part of his research is funded by the U.S. Armed Forces. Regenerative technology could be a boon to wounded soldiers. It sounds like science fiction, but one day they may even be able to regrow injured limbs and replace severely damaged organs.

Dr. Atala conducted research and practiced pediatric urology at Harvard’s Children’s Hospital Boston for 15 years, until 2003, when he became Director of the Wake Forest Institute for Regenerative Medicine in North Carolina. Dr. Atala’s numerous awards and honors include the Christopher Columbus Foundation Award, funded by the US Congress and bestowed on a living American whose discoveries will significantly benefit society; and the Scientific American, Research Leader Award, for his contributions to tissue and organ regeneration.

Tengion’s corporate headquarters and commercial manufacturing facility are in East Norriton, Pennsylvania. The company has research offices, a development laboratory and a pilot manufacturing facility in Winston Salem.